A fast-growing number of special educators nationwide are using AI to create customized education plans. Despite the risks, ...
53mon MSN
Pfizer begins late-stage trial for new pneumococcal shot in infants after strong phase 2 data
Pfizer (PFE) on Wednesday announced that it has begun a Phase 3 trial for its 25-valent pneumococcal vaccine, PF-07872412 (25vPnC), for infants after the shot outperformed its pneumococcal 20-valent ...
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results